Table 3.

Biologics and JAK inhibitors in patients with IRD, including rates and ORs of hospitalization in relation to undergoing treatment.

All Patientsa, nHospitalized Patients, nHospitalization Rate, %OR*95% CI*
IRD patients without biologics/JAK inhibitors3709280.751
JAK inhibitors1815.557.361.06–51.22
  • a Hospitalized and nonhospitalized patients, diagnosed with IRD and monitored by the Department of Rheumatology.

  • * Comparisons were between each treatment group and IRD patients without biologic/JAK inhibitor treatment. ABA: abatacept; IRD: inflammatory rheumatic disease; JAK: Janus kinase; RTX: rituximab; TNF: tumor necrosis factor.